Lane & Associates LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

Lane & Associates LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 2.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,661 shares of the company’s stock after purchasing an additional 66 shares during the quarter. Eli Lilly and Company accounts for approximately 1.3% of Lane & Associates LLC’s portfolio, making the stock its 22nd largest holding. Lane & Associates LLC’s holdings in Eli Lilly and Company were worth $2,358,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of LLY. Earnest Partners LLC raised its holdings in shares of Eli Lilly and Company by 13.8% during the 1st quarter. Earnest Partners LLC now owns 453 shares of the company’s stock valued at $352,000 after buying an additional 55 shares during the period. Caxton Associates LP acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $3,659,000. Zurich Insurance Group Ltd FI grew its stake in Eli Lilly and Company by 2.5% during the 1st quarter. Zurich Insurance Group Ltd FI now owns 234,898 shares of the company’s stock valued at $182,741,000 after purchasing an additional 5,719 shares in the last quarter. Captrust Financial Advisors grew its stake in Eli Lilly and Company by 95.8% during the 1st quarter. Captrust Financial Advisors now owns 598,834 shares of the company’s stock valued at $465,869,000 after purchasing an additional 293,050 shares in the last quarter. Finally, Kinloch Capital LLC grew its stake in Eli Lilly and Company by 59.5% during the 1st quarter. Kinloch Capital LLC now owns 909 shares of the company’s stock valued at $707,000 after purchasing an additional 339 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Down 0.3 %

NYSE:LLY opened at $748.01 on Friday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The firm has a market capitalization of $710.10 billion, a P/E ratio of 80.87, a P/E/G ratio of 2.84 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The business has a 50 day simple moving average of $865.01 and a 200 day simple moving average of $869.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. Equities research analysts predict that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is currently 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Bank of America lowered their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.